CRISPR Therapeutics AG (NASDAQ:CRSP) Given Consensus Recommendation of “Moderate Buy” by Analysts
CRISPR Therapeutics AG (NASDAQ:CRSP – Get Free Report) has been given a consensus rating of “Moderate Buy” by the eighteen ratings firms that are presently covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, seven have assigned a hold recommendation and ten have assigned a buy recommendation […]
CRISPR Therapeutics AG (NASDAQ:CRSP – Get Free Report) has been given a consensus rating of “Moderate Buy” by the eighteen ratings firms that are presently covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, seven have assigned a hold recommendation and ten have assigned a buy recommendation […]
